NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

全球抗肥胖治療市場:市場研究,預測(∼2025年),COVID-19的累積影響

Anti-Obesity Therapeutics Market Research Report, by Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2026 - Cumulative Impact of COVID-19

出版商 360iResearch LLP 商品編碼 995303
出版日期 內容資訊 英文 180 Pages
商品交期: 最快1-2個工作天內
價格
全球抗肥胖治療市場:市場研究,預測(∼2025年),COVID-19的累積影響 Anti-Obesity Therapeutics Market Research Report, by Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2026 - Cumulative Impact of COVID-19
出版日期: 2021年06月01日內容資訊: 英文 180 Pages
簡介

全球抗肥胖治療市場預計將從2020年的789.945億美元增長到2025年底的11,292.81百萬美元。

預計COVID-19將在預測期內對行業增長產生長期影響,因為這是無與倫比的全球公共衛生突發事件,幾乎影響了每個行業。我們正在進行的研究擴大了研究框架,以確保它包括潛在的COVID-19問題和潛在的未來路徑。該調查提供了有關COVID-19的見解,並考慮了消費者行為和需求,購買模式,供應鏈改路,當前市場勢力動態以及政府的主要干預措施的變化。更新後的調查提供了見解,分析,估計和預測,其中考慮了COVID-19對市場的影響。

該報告調查了抗肥胖治療的全球市場,概述了市場,分析了市場增長和障礙,市場機會,COVID-19的影響以及按區域劃分的市場規模變化。它提供系統信息,例如預測,競爭狀況和主要公司的概況。

目錄

第1章簡介

  • 調查目的
  • 市場細分和覆蓋範圍
  • 考慮調查的年份
  • 貨幣和價格
  • 語言
  • 限制
  • 利益相關者

第2章調查方法

  • 調查過程
    • 定義:調查目的
    • 決策:調查設計
    • 準備:測量設備
    • 集合:數據源
    • 分析:數據解釋
    • 公式:數據驗證
    • 已發佈:調查報告
    • 重複:報告更新
  • 進行調查
    • 開始:調查過程
    • 計劃:創建調查計劃
    • 執行:進行調查
    • 驗證:發現和分析
    • 出版物:調查報告
  • 調查結果

第3章執行摘要

  • 市場前景
  • 區域展望
  • 競爭對手展望

第4章市場概述

  • COVID-19的累積效果

第5章市場洞察

  • 市場動態
    • 促進因素
    • 抑製器
    • 市場機會
    • 挑戰
  • 搬運工五力分析
    • 新進入者的威脅
    • 替代威脅
    • 客戶的議價能力
    • 供應商的談判能力
    • 行業競爭

第6章美洲

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第7章亞太

  • 澳大利亞
  • 中國
  • 印度
  • 印度尼西亞
  • 日本
  • 馬來西亞
  • 菲律賓
  • 韓國
  • 泰國

第8章歐洲,中東/非洲

  • 法國
  • 德國
  • 意大利
  • 荷蘭
  • 卡塔爾
  • 俄羅斯
  • 沙特阿拉伯
  • 南非
  • 西班牙
  • 阿拉伯聯合酋長國
  • 英國

第9章競爭情況

  • FPNV定位矩陣
    • 象限
    • 經營策略
    • 產品滿意度
  • 市場排名分析
  • 市場份額分析
  • 競爭性SWOT分析
  • 衝突情況
    • 併購
    • 協議,合作和夥伴關係
    • 推出和增強新產品
    • 投融資
    • 獎項,獎項,擴展

第10章企業可用性簡介

  • Alizyme
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb
  • Eisai Company
  • GlaxoSmithKline PLC
  • Norgine Pharmaceuticals Ltd
  • Novo Nordisk
  • Pfizer
  • Rhythm Pharmaceuticals
  • Shionogi USA
  • Takeda Pharmaceutical
  • Vivus
  • Zafgen

第11章附錄

  • 討論指南
  • 許可證和價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MRR-EC2E133E33FA

The Global Anti-Obesity Therapeutics Market size was estimated at USD 7,898.44 Million in 2020 and expected to reach USD 8,523.36 Million in 2021, at a Compound Annual Growth Rate (CAGR) 8.25% to reach USD 12,709.09 Million by 2026.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Anti-Obesity Therapeutics to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Geography, the Anti-Obesity Therapeutics Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Anti-Obesity Therapeutics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Anti-Obesity Therapeutics Market, including Alizyme, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Eisai Company, GlaxoSmithKline PLC, Norgine Pharmaceuticals Ltd, Novo Nordisk, Pfizer, Rhythm Pharmaceuticals, Shionogi USA, Takeda Pharmaceutical, Vivus, and Zafgen.

The report provides insights on the following pointers:

  • 1. Market Penetration: Provides comprehensive information on the market offered by the key players
  • 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
  • 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  • 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
  • 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

  • 1. What is the market size and forecast of the Global Anti-Obesity Therapeutics Market?
  • 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Anti-Obesity Therapeutics Market during the forecast period?
  • 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Anti-Obesity Therapeutics Market?
  • 4. What is the competitive strategic window for opportunities in the Global Anti-Obesity Therapeutics Market?
  • 5. What are the technology trends and regulatory frameworks in the Global Anti-Obesity Therapeutics Market?
  • 6. What is the market share of the leading vendors in the Global Anti-Obesity Therapeutics Market?
  • 7. What modes and strategic moves are considered suitable for entering the Global Anti-Obesity Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

  • 3.1. Introduction
  • 3.2. Market Outlook
  • 3.3. Geography Outlook
  • 3.4. Competitor Outlook

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidences of obesity and related disorder globally
      • 5.1.1.2. Rising adoption of sedentary lifestyle due to lack of exercise
      • 5.1.1.3. Introduction of novel anti-obesity drugs
    • 5.1.2. Restraints
      • 5.1.2.1. Risk of side effects of anti-obesity therapeutics such as psychiatric disorder as well as strokes
      • 5.1.2.2. Negative perception about the anti-obesity therapeutics among the health professionals
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing clinical trials and research & development activities
      • 5.1.3.2. Increasing number of drug targets associated with clinically significant weight loss
      • 5.1.3.3. Strategic collaboration by the pharma companies
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of knowledge regarding weight management
  • 5.2. Cumulative Impact of COVID-19
  • 5.3. Porters Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry

6. Americas Anti-Obesity Therapeutics Market

  • 6.1. Introduction
  • 6.2. Argentina
  • 6.3. Brazil
  • 6.4. Canada
  • 6.5. Mexico
  • 6.6. United States
    • 6.6.1. California
    • 6.6.2. Florida
    • 6.6.3. Illinois
    • 6.6.4. New York
    • 6.6.5. Ohio
    • 6.6.6. Pennsylvania
    • 6.6.7. Texas

7. Asia-Pacific Anti-Obesity Therapeutics Market

  • 7.1. Introduction
  • 7.2. China
  • 7.3. India
  • 7.4. Indonesia
  • 7.5. Japan
  • 7.6. Malaysia
  • 7.7. Philippines
  • 7.8. South Korea
  • 7.9. Thailand

8. Europe, Middle East & Africa Anti-Obesity Therapeutics Market

  • 8.1. Introduction
  • 8.2. France
  • 8.3. Germany
  • 8.4. Italy
  • 8.5. Netherlands
  • 8.6. Qatar
  • 8.7. Russia
  • 8.8. Saudi Arabia
  • 8.9. South Africa
  • 8.10. Spain
  • 8.11. United Arab Emirates
  • 8.12. United Kingdom

9. Competitive Landscape

  • 9.1. FPNV Positioning Matrix
    • 9.1.1. Quadrants
    • 9.1.2. Business Strategy
    • 9.1.3. Product Satisfaction
  • 9.2. Market Ranking Analysis
  • 9.3. Market Share Analysis, By Quadrant
  • 9.4. Market Share Analysis, By Company
  • 9.5. Competitive Scenario
    • 9.5.1. Merger & Acquisition
    • 9.5.2. Agreement, Collaboration, & Partnership
    • 9.5.3. New Product Launch & Enhancement
    • 9.5.4. Investment & Funding
    • 9.5.5. Award, Recognition, & Expansion

10. Company Usability Profiles

  • 10.1. Alizyme
  • 10.2. Boehringer Ingelheim GmbH
  • 10.3. Bristol-Myers Squibb
  • 10.4. Eisai Company
  • 10.5. GlaxoSmithKline PLC
  • 10.6. Norgine Pharmaceuticals Ltd
  • 10.7. Novo Nordisk
  • 10.8. Pfizer
  • 10.9. Rhythm Pharmaceuticals
  • 10.10. Shionogi USA
  • 10.11. Takeda Pharmaceutical
  • 10.12. Vivus
  • 10.13. Zafgen

11. Appendix

  • 11.1. Discussion Guide
  • 11.2. License & Pricing
  • 11.3. Contact Details

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2020 VS 2026 (USD MILLION)
  • FIGURE 2. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
  • FIGURE 3. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET: MARKET DYNAMICS
  • FIGURE 4. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET: PORTERS FIVE FORCES ANALYSIS
  • FIGURE 5. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 6. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 7. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 8. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 9. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 10. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 11. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 12. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 13. CALIFORNIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 14. FLORIDA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 15. ILLINOIS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 16. NEW YORK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 17. OHIO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 18. PENNSYLVANIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 19. TEXAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 21. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 22. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 23. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 24. INDIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 25. INDONESIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 26. JAPAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 27. MALAYSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 28. PHILIPPINES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 29. SOUTH KOREA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 30. THAILAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 31. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 32. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 33. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 34. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 35. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 36. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 37. NETHERLANDS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 38. QATAR ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 39. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 40. SAUDI ARABIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 41. SOUTH AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 42. SPAIN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 43. UNITED ARAB EMIRATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 44. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 45. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET: FPNV POSITIONING MATRIX
  • FIGURE 46. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET: SHARE, BY QUADRANT, 2020
  • FIGURE 47. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET: SHARE, BY COMPANY, 2020
  • FIGURE 48. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL ANTI-OBESITY THERAPEUTICS MARKET, BY TYPE

LIST OF TABLES

  • TABLE 1. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET: MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
  • TABLE 3. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 4. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 5. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 6. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 7. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET: SCORES
  • TABLE 8. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET: BUSINESS STRATEGY
  • TABLE 9. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET: PRODUCT SATISFACTION
  • TABLE 10. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET: RANKING
  • TABLE 11. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET: SHARE, BY QUADRANT, 2020
  • TABLE 12. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET: SHARE, BY COMPANY, 2020
  • TABLE 13. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET: MERGER & ACQUISITION
  • TABLE 14. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 15. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 16. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET: INVESTMENT & FUNDING
  • TABLE 17. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 18. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET: LICENSE & PRICING
  • TABLE 19. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET: CONTACT DETAILS